Table of contents
In this issue
p503 | doi:10.1038/nrd1139
Editorial: A case for longer cycle times
p505 | doi:10.1038/nrd1138
Research Highlights
Neurodegenerative diseases: Putting the brakes on cognitive decline
p507 | doi:10.1038/nrd1141
Computational chemistry: Bespoke binding
p508 | doi:10.1038/nrd1146
Neurodegenerative diseases: Ataxin the brain
p508 | doi:10.1038/nrd1147
Structure-based drug design: A common cure for SARS?
p509 | doi:10.1038/nrd1144
Drug resistance: Pumping stations
p510 | doi:10.1038/nrd1142
Drug delivery: Controlling the flow
p510 | doi:10.1038/nrd1148
Structure-based drug design: Workings of a molecular multi-tool
p511 | doi:10.1038/nrd1145
In brief
Biotechnology | Neurodegenerative Disease | Cardiopulmonary Disease | Biotechnology
p511 | doi:10.1038/nrd1149
Biotechnology: Virus alert
p512 | doi:10.1038/nrd1143
News and Analysis
Patent watch
All for one, and one for fifteen | Keep off the pathway
p512 | doi:10.1038/nrd1150
From the analyst's couch
HIV drug market
p513 | doi:10.1038/nrd1135
Fresh from the Pipeline
Gefitinib
p515 | doi:10.1038/nrd1136
Reviews
Article series: Case Histories
Case history
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Jonathan A. Tobert
p517 | doi:10.1038/nrd1112
Implications of protein flexibility for drug discovery
Simon J. Teague
p527 | doi:10.1038/nrd1129
Article series: A guide to drug discovery
A guide to drug discovery: Making Better Drugs: Decision Gates in Non-Clinical Drug Development
J. Fred Pritchard, Malle Jurima-Romet, Mark L. J. Reimer, Elisabeth Mortimer, Brenda Rolfe & Mitchell N. Cayen
p542 | doi:10.1038/nrd1131
Targeting JNK for therapeutic benefit: from junk to gold?
Anthony M. Manning & Roger J. Davis
p554 | doi:10.1038/nrd1132
Clinical biomarkers in drug discovery and development
Richard Frank & Richard Hargreaves
p566 | doi:10.1038/nrd1130
Perspectives
Timeline
Innovation
Large-scale manufacture of peptide therapeutics by chemical synthesis
Brian L. Bray
p587 | doi:10.1038/nrd1133
Careers and Recruitment
Evolving with contemporary contract research
Ian Chapman
p597 | doi:10.1038/nrd1137
